MedTrace Logo

Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician

NCT06123936 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8400

Last updated 2023-11-14

No results posted yet for this study

Summary

This study is a clinical trial designed to assess the impact on influenza vaccination rates among people aged over 65 of a telephone text message recalling them to be vaccinated by their GP. Twenty-two GPs will be randomly selected in each arm (recall versus usual care, 1:1). Each GP will include a maximum of 210 patients by random selection from their patient list. A difference of 4 percentage points is expected between the two arms at the end vaccination campaign in the vaccination rate.

Conditions

  • Influenza Viral Infections

Interventions

OTHER

Reminder

At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software * This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software * In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address * The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit. The type of recall and the date of it will be notified in the medical file of each patient.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Laurent RIGAL, Professor · Université de Paris-Saclay

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2024-10-30
Completion
2025-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06123936 on ClinicalTrials.gov